3Dx Industries, Inc. (OTCMKTS:DDDX) is a medical technology company focused on the development and commercialization of non-respiratory wearable diagnostic solutions for early disease detection. Its core mission is to deliver point-of-care tests that utilize oral fluid biomarkers, offering a non-invasive alternative to blood draws and other traditional diagnostic methods. By integrating microfluidic and sensor technologies into a compact format, the company aims to bring rapid, accurate testing capabilities to clinical settings, community health centers, and home environments.
The flagship product, OraBD™ (Oral BioDiagnostic) system, is designed to analyze saliva samples for biomarkers linked to autoimmune disorders, infectious diseases, and metabolic conditions. This platform provides results in minutes, enabling healthcare practitioners and patients to make informed decisions without delays associated with laboratory processing. In addition to its lead assay, 3Dx Industries is advancing a pipeline of diagnostic tests targeting neurological and hormonal biomarkers, positioning the company to address a wide spectrum of health conditions with a single point-of-care device.
Originally founded in 2008 under the name InTav Technologies, the company rebranded to 3Dx Industries in 2012 and has since established strategic partnerships with universities, research institutes, and clinical laboratories across the United States. Headquartered in Durham, North Carolina, its R&D and manufacturing operations support both product development and clinical validation efforts. The executive team is led by Chairman and Chief Executive Officer Gilbert O. Nichols, whose background in biomedical innovation has guided the company’s growth. Chief Operating Officer Dr. Christopher Masback oversees technical and operational functions, while Chief Financial Officer Glenn Shook manages finance and investor relations. Under this leadership, 3Dx Industries continues to seek regulatory clearances and collaborative agreements to expand its presence in international markets.
AI Generated. May Contain Errors.
